Program
emugrobart
Also written as “RO7204239” and “GYM329”.
Its studies are mostly in Muscular Atrophy, Spinal · Muscular Dystrophy, Facioscapulohumeral · Diabetes Mellitus, Type 2 · Obesity, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 52 open or running | phase 3since Nov 1, 2021 | Dec 24, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 24, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04708847 · 30 enrolled · Netherlands
- Nov 1, 2021Phase 3 study in Muscular Atrophy, SpinalNCT05115110 · 97 enrolled · United States, Australia, Belgium and more
- Sep 16, 2022Phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT05548556 · 51 enrolled · United States, Denmark, Italy and more
- May 2, 2025Phase 2 study in ObesityNCT06965413 · 285 enrolled · United States, Poland, Spain and more
- Aug 15, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07137585 · 30 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07137585Diabetes Mellitus, Type 2 · Germany | 1 | Active, not recruiting | Sep 14, 2026 | 30 |
| NCT06965413Obesity · United States, Poland, Spain and more | 2 | Active, not recruiting | Sep 3, 2026 | 285 |
| NCT05548556Muscular Dystrophy, Facioscapulohumeral · United States, Denmark, Italy and more | 2 | Completed | May 2, 2025 | 51 |
| NCT05115110Muscular Atrophy, Spinal · United States, Australia, Belgium and more | 3 | Completed | Nov 2, 2026 | 97 |
| NCT04708847Healthy Volunteers · Netherlands | 1 | Completed | Jun 3, 2022 | 30 |
How it is read
Names in the registry
- “RO7204239”, 4 entries
- “GYM329”, 1 entry
Conditions, from the studies’ own filings
- Muscular Atrophy, Spinal, 1 study
- Muscular Dystrophy, Facioscapulohumeral, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.